Aguirre Jarrad Mattieu, the Chief Medical Officer of Lyell Immunopharma, Inc., has reported a stock sale in a recent SEC filing. This transaction, which involved the sale of 422 shares, was executed to cover tax withholding obligations from the settlement of vested restricted stock units. The average sale price was $8.63 per share. Such transactions are common among executives, particularly when it comes to managing tax liabilities.
Lyell Immunopharma, Inc. is a company focused on developing innovative therapies for cancer treatment. The firm is categorized under the pharmaceutical preparations industry, which is known for its competitive landscape and ongoing advancements in drug development. Mattieu's recent transaction is a reminder of the financial activities that occur within this sector.
The SEC filing, with accession number 0002150331-26-000003, details that the transaction took place on October 12, 2026. Following the sale, Mattieu retains ownership of 19,857 shares of the company. The filing notes that the shares were sold to meet tax obligations associated with restricted stock units that had vested.
This sale may impact perceptions of executive management at Lyell Immunopharma, particularly in terms of transparency and financial responsibility. Other executives and stakeholders in the pharmaceutical industry may also take note of this transaction as a standard practice in managing stock holdings.
Looking ahead, the filing does not specify any further actions or upcoming transactions related to Mattieu or Lyell Immunopharma. Investors and analysts will likely continue to monitor insider activities as part of their evaluation of the company’s performance and governance.